When the stocks of real companies go up more than 250%
in a year, it’s a safe bet that there are at least two factors in play –
the company has a great growth story and institutions have caught wind
of it. And so it would seem with AxoGen (AXGN),
where the company’s products for peripheral nerve repair are
legitimately exciting, but where the growth expectations are already
quite robust.
AxoGen shares seem to be pricing in a
scenario where the company holds close to one-third of its addressable
market in 2027 with FCF margins in the mid-20%s. That’s achievable, but
it doesn’t leave much room for stumbles or disappointments. I can’t make
a value case for AxoGen, but I know there are investors who care more
about story and growth, and maybe there’s still some appeal here for
that group.
Read more here:
AxoGen Offers An Exciting Story At Nosebleed Prices
No comments:
Post a Comment